Literature DB >> 18369014

Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.

P M Kavanagh1, J J Gilmartin, J O'Donnell, D O'Flanagan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18369014

Source DB:  PubMed          Journal:  Ir Med J        ISSN： 0332-3102


× No keyword cloud information.
  8 in total

1.  Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.

Authors:  Patricio Escalante; Kirstin J Kooda; Rizwana Khan; San San Aye; Stratos Christianakis; Daniel G Arkfeld; Glenn R Ehresmann; Jens J Kort; Brenda E Jones
Journal:  Lung       Date:  2014-10-16       Impact factor: 2.584

2.  Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.

Authors:  Boksoon Chang; Hye Yun Park; Kyeongman Jeon; Joong Kyong Ahn; Hoon-Suk Cha; Eun-Mi Koh; Eun-Suk Kang; Won-Jung Koh
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

3.  Necrotising fasciitis of the shoulder in association with rheumatoid arthritis treated with etanercept: a case report.

Authors:  Andrew Smyth; Diarmaid D Houlihan; Helen Tuite; Catherine Fleming; Thomas A O'Gorman
Journal:  J Med Case Rep       Date:  2010-11-17

4.  A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease.

Authors:  Mahmoud H Mosli; Othman Al-Harbi; Brian G Feagan; Majid A Almadi
Journal:  Saudi J Gastroenterol       Date:  2015 Jul-Aug       Impact factor: 2.485

Review 5.  Psoriatic disease and tuberculosis nowadays.

Authors:  Nicola Balato; Luisa Di Costanzo; Fabio Ayala; Anna Balato; Alessandro Sanduzzi; Marialuisa Bocchino
Journal:  Clin Dev Immunol       Date:  2012-05-08

Review 6.  Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

Authors:  Sasha R Fehily; Aysha H Al-Ani; Jonathan Abdelmalak; Clarissa Rentch; Eva Zhang; Justin T Denholm; Douglas Johnson; Siew C Ng; Vishal Sharma; David T Rubin; Peter R Gibson; Britt Christensen
Journal:  Aliment Pharmacol Ther       Date:  2022-05-20       Impact factor: 9.524

7.  Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates.

Authors:  Aysa Hacioglu; Sermin Borekci; Melike Melikoglu; Yesim Ozguler; Sinem Nihal Esatoglu; Serdal Ugurlu; Emire Seyahi; Izzet Fresko; Vedat Hamuryudan; Huri Ozdogan; Sebahattin Yurdakul; Ibrahim Hatemi; Aykut Ferhat Celik; H Gul Ongen; Gulen Hatemi
Journal:  Rheumatol Int       Date:  2021-07-06       Impact factor: 3.580

8.  Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines.

Authors:  Tasnim Hasan; Eric Au; Sharon Chen; Allison Tong; Germaine Wong
Journal:  BMJ Open       Date:  2018-09-12       Impact factor: 2.692
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.